Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer
This case report describes a 70-year-old man with bilateral vision loss due to cancer-associated retinopathy exacerbated by pembrolizumab.
Authors
- Jason Miller
- Thiran Jayasundera (ORCID: https://orcid.org/0000-0003-4895-4818)
- Ian Waters (ORCID: https://orcid.org/0000-0002-3341-2664)
- Jonah Yousif (ORCID: https://orcid.org/0000-0002-3471-6731)
- Mark W. Johnson (ORCID: https://orcid.org/0000-0001-9720-8761)
- Warren W. Pan (ORCID: https://orcid.org/0000-0003-4931-8864)
- Zachery R. Reichert (ORCID: https://orcid.org/0000-0003-0356-8796)
Institutions
- University of Michigan (US)
- Vision Eye Institute (AU)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1001/jamaophthalmol.2025.5068
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05